By Tom Brockbank, Henrike Granzow and Alexandrosz Czira, GPI Current treatment options and target indications Malignant melanoma is the most lethal form of skin cancer1. In the UK approximately 15,400 new cases occur per year, and since the early 1990’s the incidence rate has more than doubled (128% increase)2. The incidence varies within Europe, from … More Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective?
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape in Europe is beginning to show signs of change in how pricing … More Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This forces us all at GPI to keep on our toes and gives … More What will shape the global pharmaceutical pricing environment in 2018?